General Information of Drug (ID: DM3WKQ4)

Drug Name
Rasagiline Drug Info
Synonyms
RAS; Rasagiline [INN]; Azilect (TN); Rasagiline (INN); (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine; (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine; (R)-N-2-Propynyl-1-indanamine; 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Approved [1] , [2]
Skin cancer 2C30-2C37 Patented [3]
Skin imperfections EK71 Patented [3]
Therapeutic Class
Antiparkinson Agents
Cross-matching ID
PubChem CID
3052776
ChEBI ID
CHEBI:63620
CAS Number
CAS 136236-51-6
TTD Drug ID
DM3WKQ4
INTEDE Drug ID
DR1397
ACDINA Drug ID
D00585

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Inhibitor [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Approved [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Monoamine oxidase type B (MAO-B) DTT MAOB 9.367 6.907 8.237 8.409
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 10.036 5.779 6.508 6.481
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Monoamine oxidase type B (MAO-B) DTT MAOB 2.65E-02 1.12E-02 0.07
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6641).
2 Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
3 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
4 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
5 Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46.